A detailed history of Telos Capital Management, Inc. transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Telos Capital Management, Inc. holds 16,022 shares of VRTX stock, worth $7.22 Million. This represents 0.79% of its overall portfolio holdings.

Number of Shares
16,022
Previous 16,016 0.04%
Holding current value
$7.22 Million
Previous $7.51 Million 0.75%
% of portfolio
0.79%
Previous 0.84%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 21, 2024

BUY
$460.0 - $505.78 $2,760 - $3,034
6 Added 0.04%
16,022 $7.45 Million
Q2 2024

Jul 31, 2024

BUY
$392.81 - $485.53 $214,474 - $265,099
546 Added 3.53%
16,016 $7.51 Million
Q1 2024

Apr 24, 2024

BUY
$407.69 - $446.08 $161,852 - $177,093
397 Added 2.63%
15,470 $6.47 Million
Q4 2023

Jan 30, 2024

BUY
$343.0 - $410.68 $81,291 - $97,331
237 Added 1.6%
15,073 $6.13 Million
Q3 2023

Nov 01, 2023

SELL
$338.18 - $362.46 $30,436 - $32,621
-90 Reduced 0.6%
14,836 $5.16 Million
Q2 2023

Jul 20, 2023

SELL
$314.42 - $351.91 $104,701 - $117,186
-333 Reduced 2.18%
14,926 $5.25 Million
Q1 2023

Apr 27, 2023

SELL
$283.23 - $323.1 $238,196 - $271,727
-841 Reduced 5.22%
15,259 $4.81 Million
Q4 2022

Jan 27, 2023

SELL
$285.76 - $321.48 $12,287 - $13,823
-43 Reduced 0.27%
16,100 $0
Q3 2022

Oct 31, 2022

SELL
$273.83 - $305.53 $170,322 - $190,039
-622 Reduced 3.71%
16,143 $4.67 Million
Q2 2022

Aug 08, 2022

SELL
$234.96 - $292.55 $41,118 - $51,196
-175 Reduced 1.03%
16,765 $4.72 Million
Q1 2022

May 02, 2022

SELL
$221.42 - $260.97 $35,205 - $41,494
-159 Reduced 0.93%
16,940 $4.42 Million
Q4 2021

Jan 21, 2022

BUY
$177.01 - $223.45 $102,842 - $129,824
581 Added 3.52%
17,099 $3.76 Million
Q3 2021

Oct 19, 2021

BUY
$181.39 - $202.99 $209,686 - $234,656
1,156 Added 7.53%
16,518 $3 Million
Q2 2021

Jul 15, 2021

BUY
$187.49 - $221.1 $2.88 Million - $3.4 Million
15,362 New
15,362 $3.1 Million

Others Institutions Holding VRTX

About VERTEX PHARMACEUTICALS INC


  • Ticker VRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 256,691,008
  • Market Cap $116B
  • Description
  • Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...
More about VRTX
Track This Portfolio

Track Telos Capital Management, Inc. Portfolio

Follow Telos Capital Management, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Telos Capital Management, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Telos Capital Management, Inc. with notifications on news.